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Abstract: Heparin, the widely used pharmaceutical anticoagulant, has been in clinical use for well
over half a century. Its introduction reduced clotting risks substantially and subsequent developments,
including the introduction of low-molecular-weight heparin, made possible many major surgical
interventions that today make heparin an indispensable drug. There has been a recent burgeoning
of interest in heparin and related glycosaminoglycan (GAG) polysaccharides, such as chondroitin
sulfates, heparan sulfate, and hyaluronate, as potential agents in various applications. This ability
arises mainly from the ability of GAGs to interact with, and alter the activity of, a wide range
of proteins. Here, we review new developments (since 2010) in the application of heparin and
related GAGs across diverse fields ranging from thrombosis and neurodegenerative disorders to
microbiology and biotechnology.
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1. Introduction
Heparin, a member of the glycosaminoglycan (GAG) family of sulfated polysaccharides, is one
of the most widely used pharmaceuticals, whose major role is in the inhibition of clot formation
and thrombi, especially during surgery or following trauma. Beyond referring to some important
historical literature, this review will attempt to survey recent (by which we mean from ca. 2010 to 2017)
applications for this important and widely used drug, and will include other GAG members, which
are being explored increasingly for other potential uses.
Heparin has been an established anticoagulant drug for more than 60 years for the prevention
and control of thrombotic events owing to its interaction with a number of proteins of the blood
clotting cascade, notably antithrombin and thrombin [1]. It consists of a linear, highly sulfated
polysaccharide chain of various lengths varying from 2000 to 40,000 Da [2–4], composed of repeating
disaccharide units of 1,4 linked α-L-iduronic or β-D-glucuronic acid (D-GlcA), and α-D-glucosamine
(D-GlcN). The predominant substitution pattern comprises 2-O-sulfation of the iduronate residues and
N- and 6-O-sulfation of the glucosamine residues [5]. Heparin is also closely related structurally to
heparan sulfate (HS), which is present on cell surfaces and in the extracellular matrix. HS is generally
less sulfated than heparin and is often considered to have a defined domain structure [6–8] and
a lower proportion of L-iduronate residues. There are also D-GlcA and N-acetylated glucosamine
(D-GlcNAc) residues, as well as variations in sulfation, including a small proportion of 3-O-sulfates
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on glucosamine residues. Hyaluronic acid (HA) is the only member of the GAG family that is
not sulfated, being a homo-polymer consisting of beta (1→4) linked disaccharides of D-GlcA β
(1→3) D-GlcNAc. Chondroitin sulfate (CS) encompasses various structures, based on repeating β
(1-4) linked disaccharides of GlcA β (1→3) GalNAc containing 6-(Chondroitin sulfate-C: CS-C) and
4-sulfates (CS-A), sulfation at position-2 of the GlcA residues (GlcA2S β (1→3) GalNAc6S) (CS-D), and
4,6-di-sulfated GalNAc (GlcA β (1→3) GalNAc4, 6diS (in CS-E). The polysaccharide, dermatan sulfate
(DS), which was formerly known as CS-B, contains repeating→4) L-IdoA β (1→3) D-GalNAc β (1→
units with 4-O-sulfation on the GalNAc moiety. GAG-like structures from non-mammalian sources,
often marine, have become the focus of attention recently, and these, while possessing similar backbone
structures, often include branches of fucose units [9], which can include non-reducing terminal fucose
with sulfation at positions-2 and -3 [10].
The discovery and development of heparin as an anticoagulant agent had a tremendous impact on
health because major surgical procedures became possible, especially those in which cardiopulmonary
bypass (CPB), which was first demonstrated in animals in 1939 [11], were necessary. Another important
medical procedure that is only possible due to the anticoagulant properties of heparin is dialysis.
Indeed, unfractionated (full-length) heparin (UFH) named heparin sodium, its antidote, protamine
sulfate [12], as well as a form of low-molecular-weight heparin (LMWH) [13] all appear in the World
Health Organization’s (WHO) List of Essential Medicines. The pharmacological activity of heparin
results mainly from its ability to bind and accelerate the AT activity, thereby considerably enhancing
the inhibition of coagulation factors Xa and IIa, although it interacts in concert with AT and other
members of the blood clotting cascade as well, including factor IXa, XIa, and XIIa [14]. In a biological
rather than a clinical context though, heparin action is more closely linked to defense against exogenous
pathogens [15] and responses following tissue damage. Heparin alters cytokine levels [16], and one of
its biological roles may be to dampen the effects of the sudden release of large numbers of cytokines
following infection or sudden trauma.
In recent times, the majority of pharmaceutical heparin has been sourced from the intestine of
pigs, and detailed studies of the sequence of heparin have involved laborious separation techniques.
Recent advances in the biosynthesis of heparin-related structures employing recombinant enzymes
and synthetic uridine-diphosphate-monosaccharide donors have been developed by Liu and Linhardt,
allowing not only for the production of heparin sequences but also for the systematic and controlled
preparation of heparin (and HS) analogues, which will be suitable for a wide-range of experimental
purposes and applications [17].
2. Applications in Anticoagulation and Cancer Treatments
In current clinical use, one of the most important forms of heparin is low-molecular-weight heparin
(LMWH) which consists of a complex mixture of fragments ranging from tetra to hexadecasaccharides
and somewhat higher oligosaccharides [18–20] obtained by various chemical and enzymatic
depolymerization processes. The main advantages of LMWHs over UFH are improved bioavailability
and higher anti-factor Xa/anti-factor IIa activity ratios, with decreased hemorrhagic risk during
prolonged treatments [21]. While UFH can be monitored effectively and reversed in patients
undergoing surgery with extracorporeal circulation, LMWHs cannot, because neutralization with
protamine sulfate is ineffective. The development of new anticoagulant agents with the beneficial
properties of both UFH and LMWH is therefore still pursued and is an important area in which
biosynthetic structures are being applied [22,23].
Aside from the well-known anticoagulant activities of heparin and related GAGs or GAG mixtures,
such as sulodexide (a mixture of LMWH and DS in the ratio 80:20), heparin is also active in a wide
range of activities in which the naturally occurring cell surface polysaccharide, heparan sulfate (HS),
is a participant. Many of the proteins with which heparin interacts originate in the extracellular
matrix, the best studied of which belong to the fibroblast growth factor (FGF) family. The potential
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use of heparin to interfere with aberrant cell–cell signaling by this route has been investigated and the
relationship between sequence and activity sought [24–27].
The importance of the FGF signaling system to development and regulation, and hence when its
function is impaired or altered, also to disease is one obvious area in which heparins, acting in this
case as analogues for HS, can be applied. One area in which modulating FGF signaling would be
desirable is cancer treatment. However, it is noteworthy that cancer-related thrombotic disorders are
also well known and were first described as long ago as 1865, when the clinical association between
thrombosis and an initially undiagnosed cancer was noted. Unfractionated heparin and LMWHs
have been used successfully for the prophylaxis and treatment of cancer-related hemostatic disorders;
however, since cancer patients have an increased risk of bleeding [28], LMWHs have gained significant
ground since they produce a more predictable anticoagulant response, display improved subcutaneous
bioavailability, and exhibit an extended half-life. Furthermore, heparin-induced thrombocytopenia
(HIT) incidence is lower when LMWHs and the synthetic pentasaccharide, Fondaparinux, are used.
Novel oral anticoagulants are under development, but their efficacy and safety in cancer-patients has
yet to be proved. Despite being well recognized now, the pathogenesis is complex and results from
the combination of several factors, but the expression of tumor cell-associated clotting factors is a
shared characteristic. The prevention and treatment of these conditions extends beyond the ease of
symptoms, it has a direct impact in cancer patient survival [29], and there are some known beneficial
effects of heparin, but elucidating these is hampered by the complexity of the systems involved.
The widespread use of heparin as a treatment is hindered by unwanted anticoagulant side-effects [30]
(see also review by Afratis et al. [31]); however, the possibility of correcting signaling defects caused by
altered HS structure (e.g., by sulf enzyme activity) in cancer [32,33] or the direct inhibition of the sulf
enzymes with heparin or heparin analogues is an area of potential interest. Of direct relevance to the
progression of the disease is the inhibition of a mammalian heparanase enzyme [34], while other routes
are thought to influence metastasis, acting via P- and L-selections [35–37], inhibiting galectins [38],
inhibiting tumorogenesis and angiogenesis through cellular receptors such as CD44 and growth factor
receptors [39], or, in the case of the use of heparin as a means of ameliorating resistance to cisplatin
treatment, acting through as-yet unidentified mechanisms [40], all of which are affected by heparin
or heparin analogues. Among other GAGs, an example of the treatment of cancer is the use of the
non-sulfated GAG, hyaluronate (HA) in pancreatic ductal adenocarcinoma [41].
3. Recovery from Nervous System Damage
Recent work shows that, while CS inhibits the regeneration of neurites in the CNS, CS-bound
HB-GAM (pleiotrophin) activates them, inducing dendrite regeneration in adult cerebral cortex and
axonal regeneration in adult spinal cord [42]. Chondroitin sulfate forms a barrier following nerve
injury [43], but can be digested by enzymes to improve repair [44–47]. Chondroitin sulfate-E (CS-E),
containing unusual 4,6 di-sulfated GalNAc residues and 4-sulfated CS in aggrecan, have been shown
to be inhibitory to neurite outgrowth [48], and CS-E mediates estrogen-induced osteoanabolism [49],
suggesting several potential future applications for CS and its derivatives.
4. Respiratory Diseases
GAGs and heparin in particular have been suggested as playing a protective roles in the
inflammation response [50], which has been interpreted as involving (among other things) the
inhibition of elastase and the interaction with several cytokines [51]. Heparin and its analogues
have been proposed for the application to elastase inhibition for cystic fibrosis treatment (or other
conditions, such as acute respiratory distress syndrome (ARDS). Although they do not originate from
a conventional mammalian GAG, oligosaccharide fragments of the fucosylated GAG structures from
the sea cucumber (Holothuria forskali) [9] were shown to lower neutrophil infiltration by reducing
selectin interactions.
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5. Neurodegenerative Diseases
There is an emerging role in Parkinson's Disease for heparin acting via cathepsin-d activity
affecting α-synuclein accumulation [52], while, in Alzheimer’s Disease, the inhibition of BACE-1,
the key protease responsible for the generation of toxic Aβ fragments (1–42) is inhibited by
heparin and its derivatives [53,54], some of which have been engineered to possess very low
anticoagulant activity [55,56]. Furthermore, it is known that heparin modulates fibril formation [57],
and understanding the mechanisms underlying such events may open new routes for the prevention,
for instance, of toxic fibril formation and deposition.
6. Roles as Antimicrobial Agents
6.1. Viruses
GAGs might be expected, on the basis of their universal presence on cell surfaces, to serve as
a broad spectrum and relatively non-specific receptors for virus binding [58]; [see also an earlier
review: [59]]. Such interactions are not unexpected, since virus envelope proteins present patches
of positively charged amino acids. While GAGs have been shown to attach to filoviruses [60] and
CS-E, but not CS-D, and inhibit dengue virus infection [61], it is clear that GAGs are indeed of
relevance to the mechanisms of viral attachment and invasion. The ability of viruses to bind cell
surface HSs and, by extension, bind heparin under experimental conditions has long been known in
the case of herpes simplex (HSV) and dengue (DENV) viruses. Heparin as a potential inhibitor of
viral attachment follows naturally from these observations and has been demonstrated for DENV [62].
What is less clear is whether and how this knowledge can be exploited to enable GAGs to be applied
as inhibitors of attachment, a process that may be able to be exploited for the well-known property
of multivalency to increase the avidity of the binding of the viral particles to the GAG, perhaps
immobilized in some device, or attached to multidentate ligands in a nanotechnology format (see also
a review of this field: [63]). The potential importance of such applications is difficult to over-emphasize,
however. Recently, viral attachment to GAGs was reported for IFNα/βBP from variola (smallpox
virus), monkeypox viruses [64], and GAGs have been shown to prevent measles virus infection in cell
lines via hemagglutinin protein [65]. Other viruses, including hepatitis B, have been found to bind to
heparin [66] as has Japanese encephalitis virus (JEV) [67]. Thus, the interest in GAG-based intervention
seems set to increase.
Heparin and derivatives have been shown to be effective in preventing the infection of cells by the
influenza virus, strain H5N1 [68], and to have effects on ZIKV-induced cell death that are independent
of adhesion and invasion [69]. In this case, heparin has only a modest ability to protect infection by
analogy with dengue virus, which is also of the flavivirus family, and which interacts with heparin
through the envelope glycoproteins [70]. Rather, heparin may be acting to protect infected cells from
cytotoxic effects and cell death via the activation of cell survival signaling pathways. The ability
of heparin to protect cells from programmed cell death had already been observed in human cells
(non-infected) [71], and this may form an interesting new avenue for the application of GAG derivatives
in itself.
6.2. Parasites
The involvement of GAGs in a parasitic disease has been studied relatively little. However, the
potential for the application of GAGs remains high in cases where GAGs form a major part of the means
of attachment and invasion, especially where there is the possibility of topical application. The ability
of heparin and derivatives to inhibit rosetting of parasite infected erythrocytes has been noted [72]
and, recently, effective inhibitors (comprising fucosylated CS (FucCS)) of cytoadherence (the process
of adhesion of infected red blood cells to vascular epithelia) derived from sea cucumber have been
reported [73]. Heparin is known to alter the activity of a cysteine protease in the parasite, L. mexicana,
that causes Leishmaniasis [74] and interacts with a metalloprotease from L.(v). braziliensis [75]. Heparin
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has also been shown to accelerate protein degradation by human neutrophil elastase [76]. Several
heparin-binding proteins have also been identified in T. cruzi, where some of them are implicated in
parasite adhesion to midgut epithelial cells [77].
6.3. Bacteria
Binding of GAGs facilitates Streptococcal entry into the CNS of Drosophila [78] and determines
disease progression [79]. In relation to the phenomenon of shock, GAGs seem to be elevated overall,
perhaps originating from damaged tissue, but they also seem to neutralize antimicrobial peptides [80].
Glycosaminoglycans were studied en masse, however, without paying attention to the individual
types involved. Heparin use in sepsis patients, where crosstalk between thrombosis and inflammation
plays a critical role, has also been recognized. The use of heparin prevents the development of
microthromboembolic disease during sepsis, impairing tissue hypoxygenation and further organ
damage and dysfunction [81]. There is also literature pointing to the use of heparin-coated stents for
the prevention of bacterial biofilm formation and subsequent microbe attachment [82].
7. Panceatitis
Acute pancreatitis has been reported independently by several groups to benefit from treatment
with heparin [83] in rats and in patients [84–86]. Furthermore, LMW heparin has also been shown to
be effective [87].
8. Roles in Rheumatoid Arthritis (RA)
Naturally occurring autoantibodies to GAGs are markers in rheumatoid arthritis [88]. The level
of IgM type Ab for CS-C in serum correlates with RA, although GAG concentration alone is not a good
indicator in knee injury [89] in agreement with earlier findings in horses [90].
9. Inflammation Reduction
Many of the applications of heparin mentioned in this review may stem, at least in part, from the
ability of heparin to moderate inflammation. This topic has itself been reviewed in 2013 [91] and, in
general, heparin is perceived as acting via several routes, which include interaction with cytokines and
as an inhibitor of heparanase, to achieve reduced leukocyte recruitment.
Applications in which these properties may be important include the treatment of burns [92]
and the proposed use of heparin in asthma treatment [93]. The potential, based on a projection of the
ability of heparin to inhibit bacterial infection and reduce inflammation, to improve the symptoms of
cystic fibrosis has also been investigated [94] but no marked improvement at low doses (50,000 IU) has
been shown.
While cystic fibrosis applications acting to reduce inflammation assist sputum clearance, inhibit
elastase, or act as an inhibitor of microbial attachment or growth have not been convincing, heparin
derivatives were shown to be capable of acting at several points in the inflammatory process [51].
10. Alternative Sources of GAG-Like Structures with Potentially Useful Activities
This review attempts to cover not only new applications for heparin but also potential new
sources of active agents among the GAGs for both old and new applications. Although not all of
these structures correspond to GAGs according to the classical definitions of mammalian GAGs
provided above, GAG-like structures are found in a wide range of organisms, including Cnidaria,
Arthropoda, Mollusca, Echinodermata, and Chordata [95]. A host of polysaccharides, either GAGs in
the conventional sense or polysaccharides with structural features closely resembling GAGs, usually
bearing additional ramifications have been identified and linked to a variety of biological activities.
These include Sea cucumber (S. hermanni) as an antiinflammatory [95], marine GAG analogues [96], fish
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cartilage as an antitumor and anti-pathognic agent [97], GAGs from starfish with antithrombotic and
anti-inflammatory activities [95], and mussels (Perna canaliculis) as an anti-inflammatory agent [98].
11. Biotechnological and Other Applications
An emerging use of GAGs is in biotechnological applications, particularly in the field of embryonic
stem cells, for the regulation of differentiation [reviewed in [99]] and neural speciation in mouse
embryonic stem cells [100]. The successful fractionation of a cell population by HS epitopes has also
been reported [101]. The prospect of incorporating GAGs into electrospun meshes for the purpose
of supporting stem cell applications has also been undertaken [102]. A possible role is emerging in
muscular dystrophy, following signs of involvement of HS sulfation in the disease process and ageing,
acting via FGF-2 [103].
12. Concluding Remarks
Many a student textbook of biochemistry once dismissed the role of GAGs as merely structural;
decades of intensive research led to a burgeoning of the biological roles ascribed to them and potential
practical applications. The precise nature of the relationship between their structure and function
remains a matter of debate, a fact that stems not only from their structural complexity, but also the
difficulty of analysis, which may also indicate that new approaches are required. These approaches
may need to be sensitive to as yet undefined properties, and one such property is their large-scale
vibrational modes [104]. Nevertheless, even without this detailed information, it is clear that the
number of roles of these versatile materials seem to set to increase in the future.
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